A bibliographical application is a type of marketing authorization application in which the applicant can replace the results of their own preclinical and clinical trials with a detailed scientific bibliography. It requires that the active substances of the medicinal product have been in well-established medicinal use within the European Union for at least ten years, with recognized efficacy and an acceptable level of safety. It is also referred to as an application based on well-established medicinal use.
Legal Basis and Proof of Well-Established Medicinal Use
Article 10a of Directive 2001/83/EC allows for the waiver of preclinical and clinical trial results if the applicant can demonstrate that the active substances have a well-established medicinal use with recognized efficacy and an acceptable level of safety. This proof is not provided through a brief selection of favorable publications, but rather through a comprehensive scientific bibliography covering all relevant preclinical and clinical aspects.
The required duration of use is at least ten years within the European Union. However, this alone is not sufficient. The decisive factor is the overall assessment of the published evidence for the requested indication, dosage, pharmaceutical form, and route of administration. The literature must support the efficacy and safety of the medicinal product applied for or plausibly bridge any deviations. Modules regarding administrative and pharmaceutical quality remain an integral part of the marketing authorization dossier.
A bibliographical application is therefore not a waiver of evidence, but a different method of providing it. The authority reviews the quality, relevance, and completeness of the literature. Both positive and negative findings must be included and critically discussed. The argumentation must specifically explain why the overall data is sufficient for the specific product and the intended application.
Literature as a Component of the Dossier
The sources used must be publicly accessible and originate from recognized publications. While assessment reports from authorities can be helpful for orientation, they do not replace a valid scientific literature base. The BfArM explicitly points out that publicly available assessment reports from competent authorities, including EPARs, cannot be considered as sources for bibliographical proof.
Even proprietary, previously unpublished preclinical or clinical data are not simply part of a bibliographical justification. The applicant must systematically evaluate the researched literature, weight its significance, and disclose any gaps. For products with differing formulations, exposure, or therapeutic applications, additional justification may be required. The literature strategy is therefore a scientific dossier task and not a mere research assignment.
Differentiation from Generics, Hybrid Applications, and Biosimilars
A bibliographical application is neither a generic nor a hybrid application. In the case of a generic, the application relies on a reference to a reference medicinal product and the expiration of data exclusivity; the proof of bioequivalence is usually of central importance. In a hybrid application, the reference to the reference medicinal product is insufficient due to certain differences and is supplemented by additional data.
In contrast, a bibliographical application does not refer to a reference medicinal product, but to published scientific literature regarding well-established medicinal use. Similarly, a biosimilar follows a different evidence-based comparability concept with a biological reference medicinal product. The terms generic, generics, and biosimilar should therefore not be used as synonyms for the bibliographical application type.
This distinction also influences the dossier logic. In a bibliographical application, the focus is on the systematic presentation of published knowledge; in a generic or biosimilar application, the focus is on the comparison with the reference medicinal product. A long market history of an active substance does not, therefore, automatically make a product a generic, nor does it in itself justify a sufficient bibliographical application.
Relevance for clinical trials
The possibility of a bibliographical application changes the evidence requirements but does not replace careful development planning. Existing literature must match the intended application, and differences in the specific product must not remain unexplained. A transparent search strategy, the evaluation of contradictory results, and a robust justification of transferability are regulatorily relevant. If supplementary studies become necessary, their purpose and integration into the overall literature-based argument must be clear.
Full-service CROs such as Mediconomics provide support in evidence planning, structured literature reviews, medical writing, data evaluation, and the creation of coherent dossier modules. They can also link clinical or non-clinical supplementary data with the scientific bibliography and structure the documentation so that assumptions, limitations, and conclusions remain verifiable for the authority.
Frequently Asked Questions (FAQ)
What is the minimum duration of use required?
The active substances must have been in well-established medicinal use within the European Union for at least ten years; additionally, recognized efficacy and an acceptable level of safety must be demonstrated.
Can regulatory reports serve as a literature source?
No. According to the BfArM, publicly accessible assessment reports from competent authorities cannot be considered as sources for bibliographical proof.
Is a bibliographical application a generic application?
No. It is based on scientific literature regarding well-established medicinal use and not on a reference to a reference medicinal product.
Regulatory References
- Directive 2001/83/EC, Article 10a — allows reference to well-established medicinal use and bibliography.
- German Medicines Act (AMG), Section 22, Paragraph 3, Number 1 — contains the German regulation for the bibliographical application type.
- BfArM, Bibliographical Application — explains requirements for literature, efficacy, and safety.
